Catalyst Wire Dossier Catalyst Wire Dossier

Investigational mRNA vaccine for Respiratory Syncytial Virus and Human Metapneumovirus

mRNA vaccine targeting Respiratory Syncytial Virus and Human Metapneumovirus · Sanofi Pasteur
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Investigational mRNA vaccine for Respiratory Syncytial Virus and Human Metapneumovirus, covering 2025-09-11 to 2025-09-11. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older [Phase 1]

See pricing